Adulthood hypertension can be programmed by preeclampsia. Preeclampsia is associated with an imbalance in vasoactive factors, including nitric oxide (NO), hydrogen sulfide (H 2 S), and renin-angiotensin system (RAS). We examined whether maternal N-acetylcysteine (NAC) therapy prevented maternal suramin treatment-induced programmed hypertension in offspring and explored the effects of this therapy on NO, H 2 S, and RAS pathways in the kidneys. Pregnant Sprague-Dawley rats were intraperitoneally administered 60 mg/kg suramin alone on Gestational Days 10 and 11 and were treated with or without 1% NAC through drinking water during the entire pregnancy and lactation period. Male offspring were divided into four groups (n ¼ 8-10/group): control, suramin, NAC, and suramin plus NAC. All rat offspring were euthanized at 12 wk of age. Maternal suramin treatment induced programmed hypertension in male offspring, which was prevented by maternal NAC therapy. Suramin-induced programmed hypertension was associated with increased plasma asymmetric dimethylarginine (ADMA, an NO synthase inhibitor) level, decreased plasma Larginine-to-ADMA ratio, and decreased renal dimethylarginine dimethylaminohydrolase (an ADMA-metabolizing enzyme) activity. Protective effects of NAC against suramin-induced programmed hypertension were associated with an increase in plasma glutathione level, increase in renal 3-mercaptopyruvate sulfurtransferase level, and restoration of suramin-induced reduction in H 2 S synthesis in the kidneys. Suramin treatment exerted negligible effect on the RAS pathway in the adult male offspring kidneys. Our data suggested interplay among suramin, ADMA-NO pathway, and H 2 S synthesis pathway in programmed hypertension. Furthermore, NAC administration in pregnant rats with hypertension prevented programmed hypertension in adult offspring.
INTRODUCTION
Adulthood hypertension can be induced by early-life programming involving in utero insults and placental insufficiency [1] . Preeclampsia and gestational hypertension are hypertensive disorders induced by pregnancy. Preeclampsia is a major cause of maternal and perinatal morbidity and mortality. Despite the association between preeclampsia and offspring hypertension [2, 3] , mechanisms underlying this association remain unclear. The number of nephrons decreases in multiple animal models of developmental programming, indicating that developmental programming during nephrogenesis plays an important role in increasing susceptibility to adulthood hypertension. In the developing kidneys, maternal insults impair nephrogenesis, induce renal programming, and decrease nephron number, thus inducing programmed hypertension [4, 5] .
Several animal models of preeclampsia have been developed using different methods [6] , including activation of reninangiotensin system (RAS) by angiotensin II [7] , inhibition of nitric oxide (NO) by N G -nitro-L-arginine-methyl ester (L-NAME) [8] , and reduction of hydrogen sulfide (H 2 S) synthesis by DL-propargylglycine [9] . These findings suggest that preeclampsia is caused by an imbalance in vasoactive factors such as components of the RAS, NO, and H 2 S [6, 10] .
Suramin, a nonselective P2 purinoceptor antagonist, inhibits angiogenesis and induces placental dysfunction similar to that observed during preeclampsia [11, 12] . Suramin-induced preeclampsia involves the activation of the RAS [12] . We recently showed that maternal L-citrulline therapy prevented L-NAME-induced programmed hypertension by decreasing asymmetric dimethylarginine (ADMA, an endogenous inhibitor of NO synthase) level and increasing the L-arginine-to-ADMA ratio in the kidneys [13] . ADMA induces disturbances in uterine artery flow, and its level is elevated in mothers with preeclampsia [14] . We previously reported that impairment of ADMA-NO pathway induces programmed hypertension in both maternal calorie restriction-and streptozotocin-induced diabetic models [15, 16] . Although suramin-induced placental dysfunction and preeclampsia are associated with an imbalance in vasoactive factors and oxidative stress, it is unclear whether the ADMA-NO pathway is involved in suramin-induced developmental programming.
N-Acetylcysteine (NAC), a glutathione (GSH) prodrug, decreases blood pressure (BP) in rats with preeclampsia [17] . NAC is a precursor of L-cysteine, which is the main substrate for H 2 S production [18] . Our previous study showed that maternal NAC therapy regulated the H 2 S synthesis pathway for preventing programmed hypertension in a two-hit programming model [19] . Similar to NO, H 2 S acts as a vasodilator and contributes to BP homeostasis [20] . Homocysteine, a risk factor for preeclampsia [21] , is metabolized to L-cysteine and GSH by H 2 S-synthesizing enzymes. Because hyperhomocysteinemia is associated with preeclampsia and hypertension, it is possible that the H 2 S synthesis pathway is involved in preeclampsia-induced programmed hypertension.
Because of the crucial role of preeclampsia in fetal programming and the extended use of NAC in clinical practice, it is important to elucidate the protective effect of NAC on suramin-induced programmed hypertension in adult offspring. Therefore, the present study examined whether maternal NAC therapy prevented maternal suramin treatment-induced programmed hypertension in adult offspring and explored the effects of this therapy on the RAS, NO, and H 2 S pathways in the kidneys.
MATERIALS AND METHODS

Animals and Experimental Design
This experiment was approved by and performed under the Guidelines for Animal Experiments of Chang Gung Memorial Hospital and Chang Gung University. Virgin Sprague-Dawley rats (age, 10 wk) were obtained from BioLASCO Taiwan Co., Ltd. (Taipei, Taiwan). The rats were housed under the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC)-approved conditions with a 12L:12D cycle (dark period from 1900 to 0700). Male rats were caged with individual female rats until mating was confirmed by observation of a vaginal plug.
Pregnant rats were assigned to four groups (n ¼ 3/group); control, suramin, control plus NAC (NAC), and suramin plus NAC. First, pregnant rats (n ¼ 6) were intraperitoneally administered 60 mg/kg suramin on Gestational Days 10 and 11. The dose of suramin used in this study is based on that used in a previous study to induce preeclampsia in pregnant rats [11] . Suramin was dissolved in 100 mg/ml saline immediately before injection. Control rats (n ¼ 6) were intraperitoneally injected with 0.3 ml saline. Next, half of the rats in the suramin (n ¼ 3) and control (n ¼ 3) groups were administered 1% NAC (Sigma, St. Louis, MO) in their drinking water during the entire pregnancy and lactation period (i.e., 6 wk), which included the entire period of nephrogenesis. The dose of NAC used in this study was based on the dose used in our previous study on rats [19] , which prevented programmed hypertension induced by prenatal dexamethasone and postnatal high-fat intake. After birth, the offspring were culled into 8 pups to standardize the quantity of milk and maternal care received by each offspring. The pups were left with their mothers until weaning. Body weight (BW) of the pups was not measured at birth to prevent maternal rejection. Because hypertension occurs at a higher rate and at an earlier age in males than females [22] , only male offspring was used after weaning in subsequent experiments. Between three and five pups were examined per litter. The numbers of male offspring in control, suramin, NAC, and suramin plus NAC groups were 8, 9, 10, and 9, respectively. BP of pregnant rats was measured on Gestational Days 9 and 21 and that of male offspring was measured at 3, 4, 6, 8, 10, and 12 wk of age. BP was measured using an indirect tail-cuff method (BP-2000; Visitech Systems, Inc., Apex, NC) [13] . To ensure accuracy and reproducibility, the rats were acclimated to restraint and tail-cuff inflation for 1 wk before the experiment. Three stable measurements were obtained and were averaged. At 12 wk of age, the male offspring were anesthetized by intraperitoneally injecting ketamine (50 mg/kg) and xylazine (10 mg/kg) and were euthanized by intraperitoneally injecting an overdose of pentobarbital. The midline of the abdomen was opened, and the aorta was dissected from the adjacent vena cava, connective tissue, and fat. The aorta was cannulated using a 20-23 gauge butterfly needle, and heparinized blood samples were collected. Next, the vena cava was cut open and was perfused with phosphate-buffered saline until the kidneys were blanched. The perfused kidneys were harvested, decapsulated, divided into cortex and medulla, flash-frozen in liquid nitrogen, and stored at À808C until analysis. Before killing the male offspring, their 24-h urine was collected in a metabolic cage (Nalgene; Nalge Nunc International, Rochester, NY) for determining urinary excretion of NO 2 À , a metabolite of NO, by performing the Greiss reaction [15] . Renal 8-isoprostane level, a marker of oxidative stress, was measured using an enzyme-linked immunosorbent assay kit (Cayman, Ann Arbor, MI), according to the manufacturer's protocol. Activity of dimethylarginine dimethylaminohydrolase (DDAH, an ADMA-metabolizing enzyme) in kidney homogenates was measured by performing a colorimetric assay that measured the rate of L-citrulline production as described previously [23] . Because limited amount of kidney sample was available for each rat and because a large amount of kidney sample was needed in different experiments, only half of the rats in each group (n ¼ 5-6 per group) were used for obtaining each measurement.
High-Performance Liquid Chromatography
Plasma L-arginine, L-citrulline, ADMA, and symmetric dimethylarginine (SDMA, a stereoisomer of ADMA) levels were measured by performing highperformance liquid chromatography (HP Series 1100; Agilent Technologies, Inc., Santa Clara, CA) with an o-phthaldialdehyde/3-mercaptopropionic acid derivatization reagent [13] . Standards containing 1-100, 1-100, 0.5-5, and 0.5-5 lM of L-arginine, L-citrulline, ADMA, and SDMA, respectively, were used. The recovery rate was 95%. Tissue concentration was factored for protein concentration, which was expressed as lmol/mg protein. Plasma L-cysteine, homocysteine, and glutathione levels were also measured using highperformance liquid chromatography (HP Series 1100) as described previously [24] .
Quantitative Reverse-Transcription Polymerase Chain Reaction
RNA was extracted using TRIzol reagent treated with deoxyribonuclease I (Ambion, Austin, TX) to remove DNA contamination as described previously [13] . Next, 2 lg of the extracted RNA was reverse transcribed using SuperScript II RNase H Reverse Transcriptase (Invitrogen, Bethesda, MD) and random primers (Invitrogen) in a 40-ll reaction mixture. Control reverse transcription reactions were performed by omitting the reverse transcription enzyme. Polymerase chain reaction (PCR) was performed to confirm the absence of DNA contamination. RNA concentration and quality were determined by controlling the optical density at 260 and 280 nm. Next, complementary DNA (cDNA) was synthesized using MMLV Reverse Transcriptase (Invitrogen). Two-step quantitative PCR was conducted using iCycler iQ Multi-Color Real-Time PCR Detection System (Bio-Rad, Hercules, CA) and QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA). Expression of RAS components, including renin (Ren), prorenin receptor (Atp6ap2), angiotensinogen (Agt), angiotensin-converting enzyme (Ace), Ace2, angiotensin II type 1 (Agtr1a) and 2 (Agtr1b) receptors, and angiotensin (1-7) Mas receptor (Mas1), and that of four sodium transporters, including Na-K-2Cl cotransporter (Slc12a1), type 3 sodium hydrogen exchanger (Slc9a3), Na þ /Cl À cotransporter (Slc12a3), and Na þ /K þ ATPase a1 subunit (Atp1a1), were analyzed. The 18S rRNA gene (Rn18s) was used as a reference. Primer sequences used in this study are listed in Supplemental Table S1 (Supplemental Data are available online at www.biolreprod.org). All the samples were examined in duplicate (2.5 ll cDNA/well in a 96-well format). Relative gene expression was quantified using comparative threshold cycle (C T ) method. DC T of each sample was calculated by subtracting average C T value of each sample from the corresponding average C T value of Rn18s. DDC T was calculated by subtracting the average control DC T value from the average experimental DC T value. Fold increase in the experimental sample relative to that in the control sample was calculated using the formula 2 ÀDDCT .
Western Blot Analysis
Western blot analysis was performed as described previously [13] . Antibodies used for Western blot analysis are listed in Supplemental Table  S2 . Protein bands of interest were visualized using ECL reagents (PerkinElmer, Waltham, MA) and were quantified through densitometry (Quantity One Analysis software; Bio-Rad) as integrated optical density (IOD) after subtracting background values. The IOD was factored for Ponceau red staining to correct for any variations in total protein loading. Protein abundance was expressed as IOD/PonS.
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Renal H 2 S-Producing Capacity H 2 S-producing capacity of the kidneys was measured as described previously [19] . Briefly, the kidneys (w/v, 1:10) were homogenized in icecold 100 mM potassium phosphate buffer (pH 7.4). Tissue homogenates (430 ll) were incubated with 20 ll L-cysteine (10 mM), 20 ll pyridoxal 5 0 -phosphate (2 mM), and 30 ll saline in tightly sealed Eppendorf vials for 30 min at 378C. Next, 250 ll 1% zinc acetate was injected, followed by the injection of 250 ll 10% trichloroacetic acid to precipitate the proteins of interest and to stop the reaction. Next, 20 mM N, N 0 -dimethyl-p-phenylenediamine sulfate (20 ll) in 7.2 M HCl was added to the samples followed by the addition of 30 mM FeCl 3 (20 ll) in 1.2 M HCl. After 30 min, the absorbance was measured at 670 nm by using a spectrophotometer. Calibration curve of NaHS (3.125-250 lM) was used to calculate H 2 S concentration in each sample. The tissue concentration was factored for the protein concentration, which was expressed as nmol/(g proteinÁmin). H 2 S-synthesizing activity of 3-mercaptopyruvate sulfurtransferase (3MST) was detected using the same reagents, except Lcysteine and pyridoxal 5 0 -phosphate, which were replaced by 0.1 mM 3-mercaptopyruvate (40 ll) and dithiothreitol, respectively [19] .
Statistical Analysis
For most parameters, statistical analysis was performed using one-way ANOVA with Tukey post hoc test for multiple comparisons. BP was analyzed using two-way repeated-measures ANOVA and Tukey post hoc test. All values are expressed as mean 6 SEM. P value of , 0.05 was considered statistically significant. All the analyses were performed using statistical software package for the social sciences (SPSS, Chicago, IL).
RESULTS
Effects of Suramin and NAC on Morphological Values and BP
No difference was observed in the systolic BP of mother rats in the four groups on Gestational Day 9 (control, 124 6 8 mmHg; suramin, 131 6 3 mmHg; NAC, 121 6 7 mmHg; suramin plus NAC, 126 6 1 mmHg). Suramin treatment increased the systolic BP of mother rats in the suramin group compared with that in mother rats in the control (165 6 3 vs. 128 6 1 mmHg, P , 0.05) and NAC groups (125 6 10 mmHg, P , 0.05) on Gestational Day 21. However, this increase in maternal BP was prevented by NAC in mother rats in the suramin plus NAC group (134 6 4 mmHg, P , 0.05). Litter sizes were not significantly altered by maternal suramin treatment (pups/litter: control, 9.3 6 0.5; suramin, 10.7 6 0.7) or NAC therapy (pups/litter: NAC, 9.7 6 1; suramin plus NAC, 9.3 6 0.3). Moreover, the mortality rate in male pups was not different among the four groups ( Table 1) . BW of suramin-exposed offspring was lower than that of control offspring, which was exacerbated after NAC therapy. Kidney weight-to-BW ratio decreased in offspring in the NAC and suramin plus NAC groups compared with that in offspring in the control group. Systolic BP of offspring in the suramin group was significantly higher than that of offspring in the control group during 6-12 wk of age (Fig. 1) . This increase in BP was prevented by NAC therapy. Systolic and diastolic BPs and mean arterial pressure of offspring in the suramin group were significantly higher than those of offspring in the control groups at 12 wk of age, and this increase in BP and arterial pressure was prevented by maternal NAC therapy (Table 1) . Moreover, no differences were observed in urinary NO 2 À and renal 8-isoprostane levels among offspring in the four groups.
Effects of Suramin and NAC on the ADMA-NO Pathway
We next investigated whether suramin treatment induced an imbalance in the ADMA-NO pathway and whether maternal NAC therapy prevented this imbalance. Plasma L-citrulline and L-arginine levels were not different between offspring in the control and suramin groups ( Table 2) . Plasma ADMA and SDMA levels were significantly increased and plasma Larginine-to-ADMA ratio was significantly decreased in offspring in the suramin group compared with those in the control group. Moreover, maternal NAC therapy did not prevent alterations in plasma ADMA and SDMA levels and L-arginineto-ADMA ratio. Renal L-citrulline, L-arginine, ADMA, and SDMA levels were not different among offspring in the control, suramin, and NAC groups. However, offspring in the suramin plus NAC group showed lower renal L-citrulline, ADMA, and SDMA levels than offspring in the control group.
To determine the effect of suramin and NAC on ADMA-NO imbalance, we measured the expression and activities of proteins involved in this pathway. We observed that expression of renal cortical enzymes arginine methyltransferase-1 (PRMT1, an ADMA-synthesizing enzyme), DDAH-1, and DDAH-2 (ADMA-metabolizing enzymes) was not significantly different among offspring in the four groups (Fig. 2) . However, renal DDAH activity was lower in offspring in the suramin group than in offspring in the control group.
Effects of Suramin and NAC on the H 2 S Synthesis Pathway
Next, we examined aminothiols and enzymes involved in the H 2 S synthesis pathway. Plasma homocysteine level was not different among offspring in the four groups (Table 2) . Offspring in the suramin group showed higher plasma Lcysteine and GSH levels than those in the control group. However, maternal NAC therapy significantly decreased plasma L-cysteine levels and increased plasma GSH levels in offspring in the suramin plus NAC group compared with that in offspring in the suramin group. Because three H 2 S-synthesizing enzymes, namely, cystathionine c-lyase (CSE), cystathionine b-synthase (CBS), and 3MST, produce H 2 S by using L- 
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cysteine as the substrate, we examined the expression and activities of these enzymes in the kidneys. Protein CBS and CSE levels were not different among offspring in the four groups (Fig. 3) . Maternal NAC therapy significantly increased renal 3MST level in offspring in the NAC and suramin plus NAC groups. Unlike no difference of renal H 2 S-synthesizing enzyme expression between suramin and control, H 2 S synthesis ex vivo in kidney was reduced by suramin treatment. However, this suramin-induced decrease in H 2 S synthesis was restored after NAC therapy.
Effects of Suramin and NAC on the RAS and Sodium Transporters
We further evaluated the renal mRNA expression of RAS components and sodium transporters because they are suggested to be involved in inducing programmed hypertension [4, 5] . Ace mRNA expression was lower in the kidneys of 12-wk-old offspring in the suramin group than in those of 12-wk-old offspring in the control group (Fig. 4A) . However, renal mRNA expression of other RAS components was comparable among offspring in the four groups. Offspring in the suramin group showed significantly decreased renal Slc9a3 and Atp1a1 mRNA expression compared with offspring in the control group (Fig. 4B) . Moreover, this decreased mRNA expression was not restored by NAC therapy.
DISCUSSION
The main novel findings in this study are as follows: 1) maternal suramin treatment induced programmed hypertension in male offspring at 12 wk of age, which was prevented by maternal NAC therapy; 2) maternal suramin treatment increased plasma ADMA level, decreased plasma L-arginineto-ADMA ratio, and decreased renal DDAH activity in male offspring; 3) maternal NAC therapy increased renal 3MST level and restored suramin-induced decrease in H 2 S synthesis in the kidneys of male offspring; and 4) NAC-induced protective effects against suramin-induced programmed hypertension were associated with increased plasma GSH levels, restoration of decreased DDAH activity, and increased H 2 S synthesis in the kidneys. Consistent with the results of previous studies, which showed that preeclampsia induced programmed hypertension in adult offspring [13] , our results showed that maternal suramin treatment induced programmed hypertension in adult male offspring and that maternal NAC therapy restored suramin-induced decrease in H 2 S synthesis, suggesting that NAC therapy prevented preeclampsia-induced programmed hypertension.
Suramin is a nonselective P2 purinoceptor blocker. Recent studies indicate that ATP-P2 signaling is involved in hypertension [25] . To the best of our knowledge, the present study is the first to show that blockade of P2 receptors by suramin during pregnancy induced programmed hypertension in adult offspring, which is associated with long-term effects on the programming of the NO and H 2 S pathways in the kidneys.
Disturbed NO bioavailability because of an imbalance between L-arginine and ADMA plays a crucial role in compromising pregnancy and in programming hypertension in the offspring [5, 6, 26, 27] . ADMA is associated with fetal programming, and its level is elevated in mothers with preeclampsia [14] . Limited studies have been performed to   FIG. 1 . Effect of maternal suramin treatment and NAC therapy on systolic BP of male offspring at different ages. Suramin treatment: mother rats were treated with 60 mg/kg suramin on Gestational Days 10 and 11. NAC therapy: mother rats were administered 1% NAC in drinking water during the entire pregnancy and lactation period. Suramin plus NAC treatment: mother rats were administered both suramin and NAC. *P , 0.05 versus control group; #P , 0.05 versus suramin group (n ¼ 8-10/ group). determine the effect of suramin on the ADMA-NO pathway in programmed hypertension. To our knowledge, the present study is the first to show that suramin-induced programmed hypertension is associated with increased plasma ADMA level and decreased renal DDAH activity in adult male offspring. PRMT1 is the major isoform involved in ADMA production. Although suramin inhibits PRMT1 activity [28] , we found that maternal suramin treatment increased ADMA level in offspring, with no effect on renal PRMT1 levels. Further, ADMA is metabolized by DDAH-1 and DDAH-2, mainly in the kidneys. Consistent with our previous studies [15, 16] , we found that suramin increased ADMA levels in the kidneys by mainly decreasing renal DDAH activity, which in turn decreased ADMA degradation. Our as well as other previous studies showed that restoration of the ADMA-NO imbalance is important for preventing the development of hypertension in various programming models [5, 26, 29] . Although the present study showed that maternal NAC therapy prevented programmed hypertension in adult offspring, NAC did not exert any effect on ADMA and NO levels. Therefore, restoration of the ADMA-NO balance might not be the major mechanism underlying the protective effects of NAC against programmed hypertension. Similar to ADMA, homocysteine is a risk factor of preeclampsia [21] . However, we found that both suramin and NAC did not alter plasma homocysteine level in adult offspring. NAC performs different biological functions, in that it scavenges free radicals, reduces protein disulfide levels, exerts antioxidant effects, and acts as a precursor of GSH. We observed that NAC increased plasma GSH levels. Because maternal NAC therapy exerts long-term effects in adult offspring, it is possible that most protective mechanisms induced by maternal NAC therapy are indirect or compensatory. Importantly, our data showed that prevention of suramininduced programmed hypertension by maternal NAC therapy was associated with increased H 2 S synthesis in the kidneys. These findings are consistent with those of our previous study, which showed that maternal NAC therapy regulated the H 2 S synthesis pathway and increased plasma GSH levels in two-hitinduced programmed hypertension [19] .
Similar to NO, H 2 S plays a crucial role in BP homeostasis and preeclampsia [9, 10] . Consistent with previous studies [19, 30, 31] , our study suggested that the H 2 S synthesis pathway was involved in suramin-induced preeclampsia and programmed hypertension. However, very few studies performed to date have shown an association between suramin and the H 2 S synthesis pathway to draw any conclusion. To our knowledge, our study is the first to show that maternal suramin treatment exerted long-term effects on the H 2 S synthesis Relative PRMT1 (B), DDAH-1 (C), and DDAH2 (D) levels as well as (E) DDAH activity in the renal cortex were quantified. Suramin treatment: mother rats were administered 60 mg/kg suramin on Gestational Days 10 and 11. NAC therapy: mother rats were administered 1% NAC in drinking water during the entire pregnancy and lactation period. Suramin plus NAC treatment: mother rats were administered both suramin and NAC. *P , 0.05 versus control group (n ¼ 8-10/group).
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FIG. 4. Effect of maternal suramin treatment and NAC therapy on gene expression of RAS components (A) and sodium transporters (B) in the kidneys. Suramin treatment: mother rats were administered 60 mg/kg suramin on Gestational Days 10 and 11. NAC therapy: mother rats received 1% NAC in drinking water during the entire pregnancy and lactation period. Suramin plus NAC treatment: mother rats were administered both suramin and NAC. *P , 0.05 versus control group; #P , 0.05 versus suramin group (n ¼ 8-10/group).
FIG. 3. A)
Representative Western blots showing cystathionine b-synthase (CBS, 61 kDa), cystathionine g-lyase (CSE, 45 kDa), and 3-mercaptopyruvate sulfurtransferase (3MST, 52 kDa) bands in kidney homogenates of 3-mo-old male offspring in the control, suramin, NAC, and suramin plus NAC groups. Relative CBS (B), CSE (C), and 3MST (D) levels as well as H 2 S synthesis (E) in the renal cortex were quantified. Suramin treatment: mother rats were administered 60 mg/kg suramin on Gestational Days 10 and 11. NAC therapy: mother rats were administered 1% NAC in drinking water during the entire pregnancy and lactation period. Suramin plus NAC treatment: mother rats were administered both suramin and NAC. *P , 0.05 versus control group; #P , 0.05 versus suramin group (n ¼ 8-10/group).
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pathway in adult male offspring. Importantly, our study showed that NAC therapy increased renal 3MST level and restored suramin-induced reduction in H 2 S synthesis in the kidneys of male offspring. The protein 3MST produces H 2 S from 3-mercaptopyruvate, which is produced from L-or Dcysteine [32] . Therefore, additional studies are required to clarify whether L-or D-cysteine could be used to prevent programmed hypertension in various programming models.
Although suramin-induced preeclampsia involved the activation of the RAS [12] , we observed that maternal suramin treatment exerted negligible effect on the mRNA expression of RAS components in the kidneys of male offspring. Because a discrepancy may exist between mRNA expression and protein expression and activity, additional studies are required to clarify whether the hypertensive effect of suramin is completely independent of the RAS pathway. In addition to RAS, increased expression and activity of sodium transporters, which favor sodium retention, are associated with the development of hypertension [4] . However, we found that maternal suramin treatment decreased the mRNA expression of Slc9a3 and Atp1a1 in the kidneys of offspring, suggesting that these changes may be a compensatory response to elevated BP.
Our study has a few limitations. First, we did not examine other organs involved in BP control. The protective effect of NAC on suramin-induced hypertension may be derived from other tissues, such as the heart and vasculature. Moreover, the protective effect of NAC on H 2 S-synthesizing enzymes may be derived from other organs. Second, we did not examine all the other characteristics of preeclampsia in this study. Thus, suramin-induced hypertension in pregnant rats at least in part may represent a model of gestational hypertension. Further, we observed that BW was the lowest in offspring exposed to suramin and NAC therapy. However, the programming effect of NAC on the BW of offspring remains unclear. Our recent study showed that NAC therapy decreased BW in male offspring exposed to prenatal dexamethasone plus postnatal high-fat diet [19] . Although NAC therapy reduced the BW in adult disease models [33, 34] , it is unclear whether NAC therapy reduces the BW of mother rats and their offspring in various programmed models. Moreover, although the protective role of NAC on maternal and fetal outcome in preeclampsia are unclear in humans [35] [36] [37] , our results indicated that short-term treatment with NAC in the early stage of development provides long-term protection against suramin-induced programmed hypertension. However, further studies are needed to translate our experimental findings into clinical practice. Finally, it should be noted that different prenatal insults might not use the same pathway for inducing hypertension. Therefore, further studies should be performed using other models of preeclampsia to determine whether the NO and H 2 S pathways are common targets for preventing hypertension.
Thus, we conclude that maternal suramin treatment induced programmed hypertension in adult male offspring, which was associated with the impairment of the DDAH-ADMA pathway. Maternal NAC therapy prevented suramin-induced programmed hypertension in adult male offspring by increasing plasma GSH levels, restoring decreased DDAH activity, and increasing H 2 S synthesis in the kidneys. Our data suggested an association among suramin, ADMA-NO pathway, and H 2 S synthesis pathway, which altered the BP of adult male offspring. Thus, determination of the protective effects of NAC against suramin-induced programmed hypertension will provide a strong scientific basis for treating pregnant women with preeclampsia with NAC to prevent programmed hypertension and to improve long-term outcomes in their offspring.
